Selected Publications

Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Ishizuka JJ, Manguso RT, Cheruiyot CK, Bi K, Panda A, Iracheta-Vellve A, Miller BC, Du PP, Yates KB, Dubrot J, Buchumenski I, Comstock DE, Brown FD, Ayer A, Kohnle IC, Pope HW, Zimmer MD, Sen DR, Lane-Reticker SK, Robitschek EJ, Griffin GK, Collins NB, Long AH, Doench JG, Kozono D, Levanon EY, Haining WN. Nature. 2019 Jan;565(7737):43-48. doi: 10.1038/s41586-018-0768-9. Epub 2018 Dec 17.

Subsets of IFN signaling predict response to immune checkpoint blockade in patients with melanoma. Horowitch B*, Lee DY*, Ding M, Martinez-Morilla S, Aung TN, Ouerghi F, Wang, X, Wei W, Damsky W, Sznol M, Kluger H, Rimm DL, Ishizuka JJ. 2023 June 13; Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-23-0215.

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN. Nat Immunol. 2019 Mar;20(3):326-336. doi: 10.1038/s41590-019-0312-6.

Epigenetic silencing by SETDB1 suppresses tumor intrinsic immunogenicity. Griffin GK, Wu J, Iracheta-Vellve A, Patti JC, Hsu J, Davis T, Dele-Oni D, Du PP, Halawi AG, Ishizuka JJ, Kim SY, Klaeger S, Knudsen NH, Miller BC, Nguyen TH, Olander KE, Papanastasiou M, Rachimi S, Robitschek EJ, Schneider EM, Yeary MD, Zimmer MD, Jaffe JD, Carr SA, Doench JG, Haining WN, Yates KB, Manguso RT, Bernstein BE. Nature. 2021 May; doi: 10.1038/s41586-021-03520-4.

Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. Wu Z, Zhou J, Zhang X, Zhang Z, Xi Y, Liu JB, Ho ZV, Panda A, Qiu X, Cejas P, Canadas I, Akarca FG, McFarland JM, Nagaraja AK, Goss LB, Kesten N, Longlong S, Lim K, Liu Y, Zhang Y, Baek JY, Liu Y Patil DT, Katz JP, Hai J, Bao C, Strachler M, Qi J, Ishizuka JJ, Nakagawa H, Rustgi AK, Wong KK, Meyerson M, Barbie D, Brown M, Long H, Bass AJ. Nat Genet. 2021 May 10; doi: 10.1038.s41588-021-00859-2. Online ahead of print.

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA. J Clin Oncol. 2019 Aug 28:JCO1901021. doi: 10.1200/JCO.19.01021.

Vitamin D Intake is Associated with Decreased Risk of Immune Checkpoint Inhibitor-Induced Colitis. Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum S, Ishizuka JJ, Qazi T, Elias R, Vora K, Ruan A, Martin-Doyle W, Manos M, Eastman L, Davis M, Gargano M, Haq R, Buchbinder EI, Sullivan RJ, Ott PA, Hodi SF, Rahma OE. Cancer. 2020 Jun 22. doi: 10.1002/cncr.32966 . Published online ahead of print.

Quantitating T cell cross-reactivity for unrelated peptide antigens. Ishizuka J, Grebe K, Shenderov E, Peters B, Chen Q, Peng Y, Wang L, Dong T, Pasquetto V, Oseroff C, Sidney J, Hickman H, Cerundolo V, Sette A, Bennink JR, McMichael A, Yewdell JW. J Immunol. 2009 Oct 1;183(7):4337-45. doi: 10.4049/jimmunol.0901607. Epub 2009 Sep 4.

The structural dynamics and energetics of an immunodominant T cell receptor are programmed by its Vbeta domain. Ishizuka J, Stewart-Jones GB, van der Merwe A, Bell JI, McMichael AJ, Jones EY. Immunity. 2008 Feb;28(2):171-82. doi: 10.1016/j.immuni.2007.12.018.

A full list of PubMed publications can be found here.